A phase I study104 assessing the effect of combination treatment with a novel CEA-TCB antibody (RO6958688) and PD-L1 inhibitor (atezolizumab) in patients with heavily pretreated metastatic colorectal cancer showed increased tumour inflammation and radiological evidence of tumour reduction in patients with both MSI-H and MSS colorectal cancer treated with higher-dose combination therapy (Table 1). The gene discussed is CD274; the disease is colorectal cancer.